Was Magnesium Sulfate Withheld Before Your Child’s Early Delivery?
If your child was born prematurely — before 32 weeks of gestation — and has been diagnosed with cerebral palsy, one of the first questions an experienced birth injury attorney should ask is: Was magnesium sulfate administered before delivery?
Contact Us for a Free, Confidential Consultation
Article written by Brendan Lupetin, Esq. Brendan is a managing partner in the law firm of Lupetin & Unatin, a medical malpractice law firm located in Pittsburgh and serving Western Pennsylvania.
We handle premature birth and cerebral palsy malpractice cases on a contingency fee basis.
This is not a complicated question. It is not a matter of experimental medicine or cutting-edge science. The evidence supporting magnesium sulfate as a neuroprotective agent for premature infants has been overwhelming since at least 2008. The American College of Obstetricians and Gynecologists (ACOG) issued formal guidance endorsing its use in 2010 — guidance that was reaffirmed in 2023. A 2024 Cochrane systematic review, the highest tier of medical evidence, confirmed once again that magnesium sulfate administered before early preterm birth reduces the risk of cerebral palsy in surviving infants.
When an obstetrician or hospital fails to administer magnesium sulfate to a mother threatening delivery before 32 weeks, and that child is born with cerebral palsy, the failure to provide this treatment may constitute medical malpractice.
At Lupetin & Unatin, LLC, we represent Pennsylvania families whose children suffered preventable birth injuries. If your family’s situation resembles what is described on this page, we want to hear from you.
What Is Cerebral Palsy, and What Causes It in Premature Infants?
Cerebral palsy (CP) is a group of neurological disorders that affect movement, muscle tone, and posture. It is caused by damage to the developing brain — damage that can occur before, during, or shortly after birth. Children with cerebral palsy may have difficulty walking, speaking, swallowing, or controlling their muscles. The severity ranges from mild to profound, and its consequences are lifelong.
Premature birth is one of the most significant risk factors for cerebral palsy. The earlier the delivery, the greater the risk. Infants born before 32 weeks of gestation account for a disproportionate share of all cerebral palsy cases. Delivery prior to 32 weeks is associated with roughly one in three CP cases overall. At gestational ages below 28 weeks, the risk of cerebral palsy can approach 10%.
The reason premature infants are so vulnerable is biological: the brain’s vasculature is fragile and immature in early gestation, and the very preterm brain is especially susceptible to injury from oxygen deprivation, hemorrhage, infection, and inflammatory processes. Once that injury occurs, it cannot be undone.
That is precisely why prevention — not just treatment — matters so profoundly in obstetric care for premature deliveries.
~33% of all cerebral palsy cases involve infants born before 32 weeks of gestation
~10% risk of cerebral palsy for infants born before 28 weeks
~1,000 cases of handicapping cerebral palsy per year that could be prevented in the U.S. with universal magnesium sulfate administration — per ACOG
What Is Magnesium Sulfate, and Why Should It Have Been Given?
Magnesium sulfate (MgSO4) is a compound that obstetricians have used for decades. It is familiar to every hospital labor and delivery unit in the country. It has long been standard of care for treating preeclampsia and eclampsia — conditions involving dangerously high blood pressure in pregnancy — and for certain situations involving preterm labor.
What took longer to become fully incorporated into standard practice was its use specifically as a neuroprotective agent — meaning, using it to protect the baby’s developing brain from injury in the event of very preterm delivery. The research supporting this use has been accumulating since the mid-1990s and reached a critical mass by 2008–2009.
Three large randomized controlled trials — the gold standard of medical evidence — were published between 2003 and 2008. Individually and collectively, they demonstrated that magnesium sulfate given to mothers before anticipated early preterm delivery significantly reduced the risk of cerebral palsy in surviving infants. A meta-analysis of these trials found that magnesium sulfate reduced the risk of any cerebral palsy by approximately 30% and the risk of severe or handicapping cerebral palsy by 40–45%.
The ACOG Committee on Obstetric Practice, together with the Society for Maternal-Fetal Medicine (SMFM), issued Committee Opinion No. 455 in 2010 stating that the evidence supports administering magnesium sulfate before anticipated early preterm birth to reduce the risk of cerebral palsy in surviving infants, and directed hospitals to establish specific protocols for doing so. That guidance was reaffirmed in 2023.
In 2024, an updated Cochrane systematic review — considered the highest level of evidence in medicine — examined six randomized controlled trials involving over 6,100 children and confirmed with high-certainty evidence that magnesium sulfate reduces the risk of cerebral palsy in preterm infants.
This is not a fringe theory. This is not experimental medicine. This is the established standard of care — and it has been for well over a decade.
The ACOG Standard in Plain English
ACOG Committee Opinion No. 455 (originally published 2010, reaffirmed 2023) states that magnesium sulfate given before anticipated early preterm birth reduces the risk of cerebral palsy in surviving infants. Hospitals are directed to develop specific protocols for its administration. Failure to follow this guidance may constitute a breach of the standard of care.
How Magnesium Sulfate Works to Protect the Premature Brain
The mechanism by which magnesium sulfate protects the developing brain is not entirely singular — it appears to work through multiple pathways simultaneously. Researchers believe it stabilizes cerebrovascular function, reducing the fragility of blood vessels in the immature brain that can rupture and cause hemorrhage. It also appears to block certain receptors (N-methyl-D-aspartate receptors) involved in excitatory neurotoxicity — a process by which an excess of excitatory brain activity causes cell death. Additionally, magnesium sulfate reduces the production of inflammatory cytokines and decreases free radical production, both of which contribute to brain injury in the setting of very preterm birth.
The practical result of all these mechanisms is a meaningful, measurable reduction in the rate of cerebral palsy in children who were at risk — a reduction that was demonstrated in multiple large trials across multiple countries.
When Should Magnesium Sulfate Be Given?
This is the clinical question that hospitals and obstetricians are obligated to be able to answer — and to act on. Based on the ACOG guidance and the trials underlying it, the key parameters are:
- Gestational age: Magnesium sulfate for neuroprotection is indicated when delivery is anticipated before 32 weeks of gestation. Some protocols extend this to 34 weeks.
- Imminence of delivery: The indication arises when preterm delivery is expected or planned within approximately 24 hours. This includes women in active preterm labor, women with preterm premature rupture of membranes (PPROM), and women undergoing medically indicated preterm delivery.
- Dosing: Clinical protocols typically involve a 6-gram intravenous loading dose of magnesium sulfate followed by a 2 g/hour maintenance infusion, continued until delivery or for up to 12 hours if delivery is no longer imminent.
- Monitoring: Standard monitoring of maternal vital signs, urine output, and fetal heart rate is required during administration.
A hospital that has not established a magnesium sulfate neuroprotection protocol — or that has a protocol but fails to implement it for eligible patients — may be departing from the standard of care.
The Lesson History Teaches — and Keeps Having to Repeat
The story of magnesium sulfate neuroprotection is not unique. It is, unfortunately, a pattern that has repeated itself in obstetric medicine with painful regularity.
Consider the history of corticosteroids for fetal lung maturation. The first clinical trial demonstrating that steroids given to mothers before very preterm birth could prevent fatal neonatal respiratory distress syndrome was published in 1972. Multiple confirming studies followed over the next two decades. And yet it was not until 1994 — 22 years later — that the National Institutes of Health published consensus guidelines making antenatal steroids the standard of care.
During those 22 years, countless premature infants died from a condition that was preventable. The mechanism was known. The intervention was available. The evidence was sufficient. And yet institutional inertia, professional resistance, and the slow grinding pace of guideline adoption cost an unknowable number of children their lives.
The magnesium sulfate story repeated this pattern on a compressed timeline. The evidence was compelling by 2008. ACOG weighed in formally in 2010. But studies evaluating actual clinical adoption in the years that followed found significant variation in compliance — some institutions administering it routinely to eligible patients, others not at all.
For every eligible mother who delivered prematurely at an institution that had not yet implemented a protocol, there is a child who may have been denied a meaningful chance at a neurologically intact life. That is the human cost of institutional failure to adopt evidence-based medicine.
What Constitutes Malpractice in a Magnesium Sulfate Case?
To establish medical malpractice in a birth injury case involving failure to administer magnesium sulfate, an experienced Pennsylvania attorney will evaluate whether the following elements are present:
The threshold question is whether the mother met the clinical criteria for neuroprotective magnesium sulfate: Was she threatening or planned for delivery before 32 weeks (or 34 weeks, depending on the institution’s protocol)? Was delivery anticipated within approximately 24 hours? Absent a valid clinical contraindication, an eligible patient should have received it.
A review of the medical records will show whether magnesium sulfate was ordered and administered for neuroprotection, or whether it was not ordered, not administered, or not given in time before delivery occurred.
We work with board-certified maternal-fetal medicine specialists and obstetricians who serve as expert witnesses to evaluate whether the care provided met or departed from the applicable standard. Given ACOG’s longstanding guidance and the 2023 reaffirmation, there is a strong foundation for arguing that failure to administer magnesium sulfate to an eligible patient before 32-week delivery is below the standard of care at virtually every hospital in Pennsylvania.
This is often the most complex element. Not every premature infant who received magnesium sulfate would have been spared cerebral palsy — the treatment reduces risk significantly but does not eliminate it. Causation analysis requires expert review of the timing of delivery, the extent and type of brain injury identified on imaging, the specific form and severity of the child’s cerebral palsy, and an assessment of whether magnesium sulfate, had it been given, would have materially reduced the risk of the injury that occurred.
Cerebral palsy is a lifelong condition. Damages in these cases can be substantial, reflecting: lifetime medical and therapeutic care, adaptive equipment, residential and educational support, lost earning capacity, and the profound pain and suffering experienced by the child and family. The economic analysis of lifetime damages for a child with moderate to severe cerebral palsy routinely reaches into the millions of dollars.
What to Do If You Believe Your Child’s Cerebral Palsy Was Preventable
If your child was born prematurely and diagnosed with cerebral palsy, here are the steps we recommend:
- Request all medical records immediately. This includes prenatal records, all labor and delivery records from the hospital (not just a discharge summary — the full chart), neonatal intensive care unit records, and all imaging studies including head ultrasounds and MRI reports. You have a right to these records under Pennsylvania law.
- Do not assume the hospital will preserve records indefinitely. Medical records have retention periods, and electronic records can be purged or archived in ways that make later retrieval more difficult. Act promptly.
- Consult a birth injury attorney before speaking with the hospital’s risk management department or signing any documents they present. Hospitals and their insurers have their own legal interests that are not aligned with yours.
- Understand that the absence of a complaint in your child’s records about magnesium sulfate does not mean the issue was addressed. Many of these omissions happen quietly — the medication simply was not ordered, and no one documented the reason why.
Time Matters — Pennsylvania's Statute of Limitations
While Pennsylvania law generally allows until a minor’s 20th birthday to file a malpractice claim arising from birth injury, waiting is not advisable. Witnesses’ memories fade, records become harder to locate, and expert witnesses are engaged by defense firms early. The stronger your case, the sooner we can build it. Contact us now for a free, confidential evaluation.
About Lupetin & Unatin, LLC
Lupetin & Unatin is a boutique medical malpractice and catastrophic injury firm based in Pittsburgh, Pennsylvania. We handle a carefully selected number of cases so that every client receives the time, investigative resources, and personal attention their case demands.
Our attorneys have been recognized by the American College of Trial Lawyers, named among Pennsylvania Super Lawyers, and received Lawyer of the Year recognition for Personal Injury Litigation in Pittsburgh by Best Lawyers in America. We have recovered millions of dollars on behalf of children and families harmed by preventable medical negligence throughout Pennsylvania.
We accept birth injury and cerebral palsy cases on a full contingency fee basis. You pay nothing unless we recover compensation for your family.
Contact Us for a Free, Confidential Consultation
If your child was born prematurely before 32 weeks and has been diagnosed with cerebral palsy, and you have questions about whether magnesium sulfate was given or whether the care provided met the standard, we want to hear from you. There is no obligation and no cost for an initial consultation. Call us at (412) 281-4100 or contact us through pamedmal.com.